Mystic Ventures
Mystic Ventures is a venture capital firm established in 2021 and located in Los Angeles, California. The firm focuses on investing in the burgeoning fields of psychedelic medicine and research, driven by a belief in the therapeutic potential of psychedelics for mental health and human well-being. Mystic Ventures aims to support pre-seed and seed-stage startups that are developing innovative psychedelic treatments and experiences. By leveraging a vast network and expertise across various sectors, including academia and medicine, the firm is positioned to access a growing array of opportunities within this rapidly evolving market. The firm recognizes the significant potential for growth in the psychedelic industry, which has gained traction in recent years due to increased interest and support from diverse stakeholders. Mystic Ventures prioritizes collaboration with dynamic founders and industry experts to validate investment theses and foster the success of its portfolio companies.
Top Stages
33 past transactions
Psylo
Seed Round in 2024
Psylo is a drug development company that specializes in next-generation psychedelics aimed at treating mental illness. The company focuses on creating novel therapeutic solutions for psychiatric and neurological disorders, with an emphasis on non-hallucinogenic and rapid-acting agents. Psylo's mission is to develop improved medications that can serve as effective alternatives to traditional selective serotonin reuptake inhibitors (SSRIs), thereby enhancing treatment options for mood disorders, addiction, and certain neurological diseases. By leveraging psychedelic molecules as the foundation for its innovative therapies, Psylo seeks to make significant advancements in mental health treatment.
Spiritus Bioscience
Venture Round in 2023
Spiritus Bioscience is a biotechnology company focused on developing novel psychedelic therapeutics. It specializes in proprietary drug-delivery technologies aimed at enhancing patient experience and safety in mental health treatments, with a current focus on Medicalized-Psilocybin in Oregon.
Awakn Life Sciences
Post in 2023
Awakn Life Sciences is a clinical-stage biotechnology company dedicated to developing and delivering innovative psychedelic medicine aimed at treating addiction, with a primary focus on Alcohol Use Disorder (AUD). The company comprises a multidisciplinary team of chemists, scientists, psychiatrists, and psychologists who are working to create the next generation of psychedelic drugs and therapies, as well as the technologies that enable their use. Recognizing the inadequacies of current treatment options for AUD, Awakn aims to provide breakthrough therapeutics for individuals suffering from addiction, addressing a significant medical need both in the United States and internationally.
2A Biosciences
Seed Round in 2023
2A Biosciences is a pharmaceutical company founded in 2022 and based in California, USA. It specializes in developing small molecule drugs aimed at treating inflammatory diseases by utilizing 2A agonists that target the serotonin system. Currently operating in stealth mode, the company is focused on advancing its innovative therapeutic solutions to address various inflammatory conditions.
Sama Therapeutics
Pre Seed Round in 2023
Sama Therapeutics is a developer of precision neuropsychiatry solutions that leverages artificial intelligence and machine learning to enhance the efficacy of clinical trials for neuropsychiatric treatments. The company focuses on preventing trial failures and reducing costs by accurately profiling participants who are likely to respond to specific treatments. Its advanced multimodal data processing and analysis software utilizes generative AI and deep learning transformers to synthesize and validate predictive biomarkers derived from diverse data sources, including electroencephalograms (EEG), electrocardiograms (ECG), multi-omics, and behavioral data. Through these innovative approaches, Sama Therapeutics aims to improve the quality of psychiatric treatments available to clinicians, ultimately enhancing patient outcomes in the field of neuropsychiatry.
Heading Health
Venture Round in 2023
Heading Health is a technology-enabled mental health platform dedicated to enhancing access to affordable care. The company provides personalized treatment solutions that utilize evidence-based therapeutics and advanced technologies such as transcranial magnetic stimulation, telepsychiatry, and intramuscular ketamine. By leveraging these tools, Heading Health aims to deliver effective and convenient mental health services, helping patients achieve meaningful outcomes and improved well-being.
DopaGE
Seed Round in 2023
DopaGE is an education technology company focused on overdose prevention and response, specifically targeting academic institutions. Its platform provides a cloud-based, gamified curriculum designed to teach students how to prevent, recognize, and respond to drug overdoses, a leading cause of death among GenZ and Millennials. Developed by experts in emergency medicine and neuroscience, DopaGE's engaging content aims to empower students with the knowledge and confidence needed to address overdose situations effectively. By making this vital education accessible and easily implementable, DopaGE seeks to significantly reduce overdose incidents on college campuses and contribute to overall public health.
Journey Clinical
Series A in 2023
Journey Clinical is a platform that provides services to member psychotherapy practices that are independently owned and operated, and in no way owns, directs, or controls the mental healthcare clinicians providing care.
CB Therapeutics
Series A in 2023
CB Therapeutics is a biotechnology company focused on the biosynthetic production of cannabinoids and tryptamines using a cellular agriculture platform. By employing yeast and sugar as raw materials, the company produces pure cannabinoids such as CBD and THC, eliminating the need for plant cultivation. This innovative approach allows CB Therapeutics to develop cannabinoids and their analogs for the treatment of various diseases, particularly those related to mental health. The company's efforts aim to advance clinical research and contribute to addressing serious health conditions, ultimately enhancing healthspan and improving patient outcomes in the healthcare industry.
Nucleus
Seed Round in 2023
Nucleus is a venture studio focused on supporting emerging companies in the psychedelic ecosystem. It provides a range of services that facilitate connections within the psychedelics industry, including therapy, education, and access to a community of investors. By incubating these companies, Nucleus aims to advance alternative medicines and promote mental health solutions, helping them establish strong brands and contribute to the growing community dedicated to the responsible use of psychedelic therapies.
Enthea
Seed Round in 2022
Enthea is a company that focuses on enhancing mental health treatment options by providing access to safe and affordable psychedelic-assisted therapy as a workplace benefit. It partners with businesses to offer benefit plans that cover therapeutic services, facilitating coverage for employees seeking these critical mental health treatments. Enthea has developed a trusted network of certified practitioners specializing in Ketamine-Assisted Therapy and Psychedelic-Assisted Therapy. By building these networks and creating benefit plans for early adopter employers, Enthea aims to accelerate the acceptance and integration of psychedelic therapies into mainstream healthcare, ensuring consumers can access necessary treatments more easily and affordably.
Spiritus Bioscience
Seed Round in 2022
Spiritus Bioscience is a biotechnology company focused on developing novel psychedelic therapeutics. It specializes in proprietary drug-delivery technologies aimed at enhancing patient experience and safety in mental health treatments, with a current focus on Medicalized-Psilocybin in Oregon.
Psilera
Funding Round in 2022
Psilera is a biopharmaceutical company dedicated to developing innovative therapeutics for neurodegenerative diseases through the use of psychedelic compounds. The company focuses on creating a new class of neurological medicines, with its lead asset, PSIL-006, being a non-hallucinogenic derivative of psilocybin aimed at treating frontotemporal dementia. Psilera’s approach involves repurposing psychoactive natural products as foundational elements for next-generation therapies that enhance mental health. By prioritizing scientific excellence, Psilera seeks to transform the lives of individuals affected by cognitive, mood, and substance use disorders, marking a significant advancement in the field of mindful medicine.
Beckley Retreats
Seed Round in 2022
Beckley Retreats is a provider of virtual integration programs designed to support individuals with neurological and psychiatric disorders. The company specializes in facilitating safe and legal psychedelic retreats that offer scientific insights into healing practices. Beckley Retreats emphasizes holistic training and dedicated care, ensuring that participants have access to necessary medical support. Additionally, the company provides training and certification programs for practitioners, equipping them with the skills needed to guide others through their healing journeys.
Maya Health
Seed Round in 2022
Naitur.ai is a company focused on enhancing psychedelic healthcare through a specialized practice management platform. Founded in 2019 and based in Denver, Colorado, the platform allows practitioners to track, manage, and measure health outcomes effectively. It offers personalized protocols and psychedelic-specific assessments that help in monitoring dosages, wellness outcomes, and psychological metrics. By streamlining these processes, Naitur.ai aims to reduce the workload for psychedelic practitioners, enabling them to serve a larger number of clients and improve mental health and well-being in the communities they support.
CB Therapeutics
Venture Round in 2022
CB Therapeutics is a biotechnology company focused on the biosynthetic production of cannabinoids and tryptamines using a cellular agriculture platform. By employing yeast and sugar as raw materials, the company produces pure cannabinoids such as CBD and THC, eliminating the need for plant cultivation. This innovative approach allows CB Therapeutics to develop cannabinoids and their analogs for the treatment of various diseases, particularly those related to mental health. The company's efforts aim to advance clinical research and contribute to addressing serious health conditions, ultimately enhancing healthspan and improving patient outcomes in the healthcare industry.
Sempera Organics
Seed Round in 2022
Sempera Organics is a vertically integrated lab farm dedicated to producing high-quality, certified organic mushroom ingredients and products. The company focuses on sustainability with a zero-waste approach, offering a variety of mushroom options designed for both wet and dry applications. Sempera Organics specializes in pure mushroom powders, proprietary blends, and extracts, all available in bulk quantities. Its products cater to the functional foods, nutraceuticals, and cosmeceuticals industries, providing clinically relevant mushroom ingredients. By prioritizing environmentally friendly cultivation methods and a streamlined purchasing process, Sempera Organics aims to deliver reliable and effective solutions to its consumers.
Freedom Biosciences
Seed Round in 2022
Freedom Biosciences is a biotechnology company focused on developing next-generation psychedelic therapeutics. The company aims to create advanced psychedelic pharmaceuticals by harnessing the established pharmacology of compounds such as ketamine. Its mission is to provide innovative treatment options for medical professionals working with patients suffering from resistant depression and various mental disorders. Through its platform, Freedom Biosciences seeks to contribute to the evolving landscape of mental health treatment, addressing the needs of individuals who do not respond to conventional therapies.
Journey Clinical
Series A in 2022
Journey Clinical is a platform that provides services to member psychotherapy practices that are independently owned and operated, and in no way owns, directs, or controls the mental healthcare clinicians providing care.
Heading Health
Seed Round in 2022
Heading Health is a technology-enabled mental health platform dedicated to enhancing access to affordable care. The company provides personalized treatment solutions that utilize evidence-based therapeutics and advanced technologies such as transcranial magnetic stimulation, telepsychiatry, and intramuscular ketamine. By leveraging these tools, Heading Health aims to deliver effective and convenient mental health services, helping patients achieve meaningful outcomes and improved well-being.
Stillmind Therapeutics
Pre Seed Round in 2022
Developer of an AI-enabled healthcare technology designed for precision medicines. The company's technology employs AI, automation, and biology-first principles to develop medicines by targeting molecular patient subtypes, beginning with bipolar disorder, enabling the healthcare industry to improve patient care affected by brain disorders.
Multiverse
Seed Round in 2022
Multiverse is a digital marketplace that focuses on functional mushrooms, providing a variety of products including superfoods, snacks, supplements, and accessories. The company aims to popularize functional mushrooms and foster collaboration within the psychedelics industry. Multiverse positions itself as the world's first dedicated platform for functional mushrooms, promoting not only their health benefits but also integrating a culture around them through unique offerings such as health supplements and streetwear items. This approach reflects a commitment to making these products appealing and accessible to a broader audience.
Heading Health
Series A in 2022
Heading Health is a technology-enabled mental health platform dedicated to enhancing access to affordable care. The company provides personalized treatment solutions that utilize evidence-based therapeutics and advanced technologies such as transcranial magnetic stimulation, telepsychiatry, and intramuscular ketamine. By leveraging these tools, Heading Health aims to deliver effective and convenient mental health services, helping patients achieve meaningful outcomes and improved well-being.
Adamo Bioscience
Seed Round in 2022
Adamo Bioscience is a pharmaceutical company focused on developing innovative treatments for Hypoactive Sexual Desire Disorder (HSDD). The company is engaged in researching psychedelic compounds and technology solutions aimed at enhancing interpersonal connections and promoting emotional healing. Adamo Bioscience offers a range of products and services designed to foster love and strengthen relationships, as well as to address and heal sexual trauma. Through its unique approach, the company seeks to empower individuals to improve their relationships and overall emotional well-being.
Psychedelic Water
Series A in 2022
Psychedelic Water is a pioneering brand in the legal psychedelic beverage industry, focused on creating non-alcoholic drinks that promote mild mood enhancement and relaxation. The company's products combine kava root, damiana leaf, and green tea leaf extract, offering consumers an uplifting experience without the hangover associated with alcoholic beverages. Psychedelic Water aims to provide a unique alternative for both work and leisure, delivering a sense of euphoria, mental clarity, and creative stimulation through its carefully crafted formulations. By embracing the ethos that psychedelics can be enjoyable and beneficial, Psychedelic Water seeks to redefine social drinking and promote a more conscious approach to mood enhancement.
Multidisciplinary Association for Psychedelic Studies
Funding Round in 2022
MAPS is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. The organization is focused on developing psychedelics and marijuana into prescription medicines, training therapists and working to establish a network of treatment centers, supporting scientific research into spirituality, creativity, and neuroscience, and educating the public honestly about the risks and benefits of psychedelics and marijuana. MAPS was founded in 1986 by Rick Doblin and is headquartered in Santa Cruz, California.
Entheo Digital
Seed Round in 2022
Driving Innovation at the Intersection of VR, Data, and Mental Health
Breathwrk
Funding Round in 2022
Breathwrk, Inc. is a company based in Venice, California, that specializes in developing a mobile application focused on guided breathing exercises. Founded in 2019, the Breathwrk app offers science-backed techniques designed to enhance mental and physical wellness. Users can access a variety of easy-to-follow exercises aimed at alleviating anxiety, promoting better sleep, increasing energy levels, and improving mood. The application also addresses issues related to athletic performance, stress management, and mental clarity, making it a versatile tool for individuals seeking to improve their overall well-being. Through its innovative approach to breath work, Breathwrk empowers users to take control of their mental and physical health.
Lykos Therapeutics
Funding Round in 2022
Lykos Therapeutics is a biopharmaceutical company dedicated to transforming mental health treatment. With over three decades of experience exploring therapies assisted by psychedelics, they focus on rigorous scientific research to develop innovative medicines and therapeutic techniques for mental health disorders. Their mission is to revolutionize current practices by creating novel treatment alternatives and integrating these into the healthcare system.
FireflyVr
Seed Round in 2022
FireflyVR is a company dedicated to creating virtual reality experiences that positively impact physical health, mental well-being, education, and research. Their team, comprised of video game veterans, focuses on developing innovative technologies in collaboration with health and technology partners. FireflyVR's flagship product, The Sanctuary, is a Virtual Reality experience designed to prepare patients for ketamine treatments by reducing pre-procedure anxiety and enhancing therapeutic outcomes through cognitive behavioral therapy techniques. The company aims to adapt this modular platform to support various dissociative medicines and therapies, starting with treatment-resistant depression, and ultimately expanding its impact across multiple health indications.
Wake Network
Series A in 2021
Wake Network, Inc. is a Toronto-based company that specializes in clinical research and the development of wellness solutions through fungi and plant-based medicine. Founded in June 2018, it combines expertise from wellness professionals and advanced technology to create innovative healing benefits for the mind and body. The company has established a regenerative feedback loop, enabling it to conduct research, monitor outcomes, and integrate findings from clinical studies on a personalized basis. This approach positions Wake Network at the forefront of advancements in mental and holistic health.
HOLOS
Seed Round in 2021
HOLOS is a boutique wellness center that specializes in immersive body and mind programming, emphasizing plant medicine experiences. The center focuses on consciousness expansion and healthy living, offering retreats designed to facilitate transformation and healing. Drawing on modern neuroscience and indigenous wisdom, HOLOS provides an environment that supports guests in their personal growth journeys. Through its unique approach, the company aims to establish a new standard in wellness, integrating various practices to enhance overall well-being.
Psychedelic Water
Series A in 2021
Psychedelic Water is a pioneering brand in the legal psychedelic beverage industry, focused on creating non-alcoholic drinks that promote mild mood enhancement and relaxation. The company's products combine kava root, damiana leaf, and green tea leaf extract, offering consumers an uplifting experience without the hangover associated with alcoholic beverages. Psychedelic Water aims to provide a unique alternative for both work and leisure, delivering a sense of euphoria, mental clarity, and creative stimulation through its carefully crafted formulations. By embracing the ethos that psychedelics can be enjoyable and beneficial, Psychedelic Water seeks to redefine social drinking and promote a more conscious approach to mood enhancement.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.